The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001## wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

##STR00001##

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity. ##STR00001##

An organic electroluminescence device includes: an anode; an emitting layer; and a cathode, the emitting layer containing a first material, a second material and a third material, the first material being a fluorescent material, the second material being a delayed fluorescent material, the third material having a singlet energy larger than a singlet energy of the second material.

An organic electroluminescence device includes: an anode; an emitting layer; and a cathode, the emitting layer containing a first material, a second material and a third material, the first material being a fluorescent material, the second material being a delayed fluorescent material, the third material having a singlet energy larger than a singlet energy of the second material.

The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.

The present invention relates to a substituted benzimidazole derivative as represented by formula (I) and a pharmaceutically acceptable salt, a polymorph, a tautomer, a stereoisomer, a hydrate, a solvate or an isotopic variant of the derivative. The compound is a PPAR α and/or PPAR δ agonist, therefore the compound can be used for treating and/or preventing diseases associated with by PPAR α and/or PPAR δ, such as non-alcoholic steatohepatitis, Duchenne muscular dystrophy syndrome, Alzheimer's disease, tumors and PBC (primary biliary cholangitis)

##STR00001##

The present invention relates to a substituted benzimidazole derivative as represented by formula (I) and a pharmaceutically acceptable salt, a polymorph, a tautomer, a stereoisomer, a hydrate, a solvate or an isotopic variant of the derivative. The compound is a PPAR α and/or PPAR δ agonist, therefore the compound can be used for treating and/or preventing diseases associated with by PPAR α and/or PPAR δ, such as non-alcoholic steatohepatitis, Duchenne muscular dystrophy syndrome, Alzheimer's disease, tumors and PBC (primary biliary cholangitis)

##STR00001##

A light emitting device and a light emitting display device that are capable of improving efficiency, driving voltage, and lifespan by varying the configuration of a layer adjacent to a blue light emitting layer in a blue fluorescent stack contacting a cathode are disclosed. The light emitting device includes stacks between an anode and a cathode, wherein an n.sup.th stack contacting the cathode is a first blue stack that includes a first hole transport layer, a first electron-blocking layer, a first blue light emitting layer containing a boron-based dopant having an emission peak of 430 nm to 480 nm, a first electron transport layer contacting the first blue light emitting layer, and an electron injection layer having two sides contacting the first electron transport layer and the cathode, respectively, wherein the first electron transport layer contains a mixture of a first material and a second material.

A light emitting device and a light emitting display device that are capable of improving efficiency, driving voltage, and lifespan by varying the configuration of a layer adjacent to a blue light emitting layer in a blue fluorescent stack contacting a cathode are disclosed. The light emitting device includes stacks between an anode and a cathode, wherein an n.sup.th stack contacting the cathode is a first blue stack that includes a first hole transport layer, a first electron-blocking layer, a first blue light emitting layer containing a boron-based dopant having an emission peak of 430 nm to 480 nm, a first electron transport layer contacting the first blue light emitting layer, and an electron injection layer having two sides contacting the first electron transport layer and the cathode, respectively, wherein the first electron transport layer contains a mixture of a first material and a second material.